Ann: Last Patient Completes Treatment in NTIPANS1 Clinical Trial, page-6

Lev,

Autism/ASD they say effects 1 in 44 children.
In our NDIS system of currently around 550k people, it costs the government $35B per year, some $3b per month or $100m per day. Of these 550k people, roughly 250k have some form of ASD.
Of these there are about 130k children with ASD in our trial bracket. These 130k children in the NDIS are costing our government alone around $6b per year , or $500m per month, which is around $17m per day.
Please lets see if we can only reduce that by 20% and we save the government $1.2b per year, that does not include any adults with ASD, and that's only in OZ
This also does not include the costs of medicines to treat these people, and all the additional costs to family, friends and the charities helping these people.

If we can help reduce any of these sufferers symptoms, we will significantly help families and the community as a whole-- what is that market worth --- if right we are the next multi unicorn.

Oh back to Pandas/Pans-- any google search says this effects 1 in 200 children.
There are no FDA/EMA approved drug therapies for Pandas/Pans

While not as big as ASD and it may not be as prevalent, I believe its still a multi $B market, just look at the size of NEU's market -- I think in the US around 5000 cases per year-- and its look at it's market cap, -- with limited success.

Also P/P would appear to be eligible for Orphan Drug status, which means, if successful, we may get "fast tracked" to commercialisation.

Just a dreamer.